BioRestorative Therapies Reports Q2 Results, Announces Conference Call
Ticker: BRTX · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1505497
Sentiment: neutral
Topics: financial-results, 8-K
TL;DR
BRTX dropped Q2 results, call scheduled for Aug 6.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on August 6, 2024, reporting on its second quarter results and announcing a conference call. The filing details financial conditions and results of operations for the period ending August 6, 2024.
Why It Matters
This filing provides investors with an update on the company's financial performance and operational status, crucial for assessing its current health and future prospects.
Risk Assessment
Risk Level: medium — The filing is a routine update on financial results, but the company's specific financial health and operational progress are not detailed enough in this summary to assess higher risk.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 40 Marcus Drive Melville, New York 11747 (address) — Principal executive offices
- ( 631 ) 760-8100 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on BioRestorative Therapies, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosure and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 6, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 40 Marcus Drive, Melville, New York 11747.
What is the company's telephone number?
The company's telephone number is (631) 760-8100.
What state is BioRestorative Therapies, Inc. incorporated in?
BioRestorative Therapies, Inc. is incorporated in Nevada.
Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-08-06 16:47:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- brt8624.htm (8-K) — 25KB
- ex99_1.htm (EX-99.1) — 1KB
- brtpr1.jpg (GRAPHIC) — 918KB
- brtpr2.jpg (GRAPHIC) — 729KB
- 0001021771-24-000158.txt ( ) — 2427KB
- brtx-20240806.xsd (EX-101.SCH) — 4KB
- brtx-20240806_lab.xml (EX-101.LAB) — 22KB
- brtx-20240806_pre.xml (EX-101.PRE) — 16KB
- brt8624_htm.xml (XML) — 4KB
02
Item 2.02. Result of Operations and Financial Condition. On August 6, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release announcing that its financial results for the second quarter ended June 30, 2024 will be released after market close on Tuesday, August 13, 2024 (the "Press Release"). The Press Release included details with regard to a conference call to be hosted by the Company's management following the release. On the call, the Company's management will review the financial results and provide a business update. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01
Item 7.01 Regulation FD Disclosure . See Item 2.02 above. The information in the Press Release is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Press Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K with respect to the Press Release is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Press Release is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated August 6, 2024, issued by BioRestorative Therapies, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: August 6, 2024 By: /s/ Robert Kristal Robert Kristal Chief Financial Officer